Method for stimulating T lymphocytes with IL-2
The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.
1. A method for stimulating regulatory T lymphocytes (Tregs) in a human subject suffering from type T diabetes, the method comprising subcutaneously administering interleukin-2 (IL-2) to the human subject at a dose of between 0.1 and 3.5 MIU/day in a first course of treatment, wherein the first course of treatment is followed by a maintenance dose, wherein the first course of treatment consists of an administration of IL-2 once per day for at least 3 consecutive days, and wherein the maintenance dose is given to the subject once a week or once or twice a month.
2. The method of claim 1 , wherein the human subject is administered with IL-2 at a dose of 3 MIU/day in the first course of treatment.
3. The method of claim 1 , wherein the human subject is administered with IL-2 at a dose of less than 2 MIU/day in the first course of treatment.
4. The method of claim 1 , wherein the subject is administered with IL-2 at a dose of between 0.25 and 3.5 MIU/day in the first course of treatment.
5. The method of claim 1 , wherein the first course of treatment consists of an administration of IL-2 once per day for 3 to 7 days.
6. The method of claim 1 , wherein the maintenance dose starts 1 to 4 weeks after the last dose of the first course of treatment.
7. The method of claim 1 , wherein the subject is administered with IL-2 at a dose of 1.5 MIU/day in the first course of treatment.
8. The method of claim 1 , wherein the subject is a child.
9. The method of claim 1 , wherein the maintenance dose is given to the subject once a week.
10. The method of claim 1 , wherein the maintenance dose is given to the subject once or twice a month.
11. A method for stimulating regulatory T lymphocytes (Tregs) in a human subject suffering from type I diabetes, the method comprising subcutaneously administering interleukin-2 (IL-2) to the human subject at a dose of between 0.05 and 2 MIU/m 2 /day in a first course of treatment, wherein the first course of treatment is followed by a maintenance dose, wherein the first course of treatment consists of an administration of IL-2 once per day for at least 3 consecutive days, and wherein the maintenance dose is given to the subject once a week or once or twice a month.
12. The method of claim 11 , wherein the subject is administered with IL-2 at a dose of between 0.2 and 1 MIU/m 2 /day in the first course of treatment.
13. The method of claim 11 , wherein the human subject is administered with IL-2 at a dose of 0.2 to 0.6 MIU/m 2 /day in the first course of treatment.
14. The method of claim 11 , wherein the subject is a child.
15. The method of claim 11 , wherein the first course of treatment consists of an administration of IL-2 once per day for 3 to 7 days.
16. The method of claim 15 , wherein the maintenance dose starts 1 to 4 weeks after the last dose of the first course of treatment.
17. The method of claim 11 , wherein the maintenance dose is given to the subject once a week.
18. The method of claim 11 , wherein the maintenance dose is given to the subject once or twice a month.